Aptose Biosciences (NASDAQ:APTO) Earns Hold Rating from Analysts at StockNews.com

Stock analysts at StockNews.com began coverage on shares of Aptose Biosciences (NASDAQ:APTO) (TSE:APS) in a research note issued to investors on Sunday. The firm set a “hold” rating on the biotechnology company’s stock.

Several other equities research analysts also recently commented on the stock. Canaccord Genuity Group lowered their price objective on shares of Aptose Biosciences from $15.00 to $6.00 and set a “buy” rating for the company in a research note on Thursday, May 16th. Piper Sandler reiterated an “overweight” rating and set a $5.00 price objective on shares of Aptose Biosciences in a research note on Wednesday, April 3rd. Finally, HC Wainwright reiterated a “buy” rating and set a $7.00 price objective on shares of Aptose Biosciences in a research note on Friday, June 14th. One equities research analyst has rated the stock with a hold rating and six have given a buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $14.83.

Aptose Biosciences Trading Up 1.2 %

NASDAQ:APTO opened at $0.76 on Friday. Aptose Biosciences has a 12 month low of $0.71 and a 12 month high of $5.10. The firm has a fifty day simple moving average of $1.05 and a 200-day simple moving average of $1.60. The company has a market capitalization of $13.75 million, a P/E ratio of -0.12 and a beta of 1.39.

Aptose Biosciences (NASDAQ:APTO) (TSE:APS) last posted its quarterly earnings data on Tuesday, May 14th. The biotechnology company reported ($0.73) EPS for the quarter, topping the consensus estimate of ($0.82) by $0.09. Equities analysts forecast that Aptose Biosciences will post -2.67 EPS for the current year.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Aptose Biosciences stock. Annandale Capital LLC raised its position in Aptose Biosciences Inc. (NASDAQ:APTO) (TSE:APS) by 40.0% in the third quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 74,666 shares of the biotechnology company’s stock after buying an additional 21,334 shares during the period. Annandale Capital LLC owned about 0.99% of Aptose Biosciences worth $209,000 at the end of the most recent quarter. 26.62% of the stock is owned by hedge funds and other institutional investors.

Aptose Biosciences Company Profile

Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.